Effects Of Canagliflozin On Cardiovascular, Renal, And Safety Outcomes In Participants With Type 2 D

In patients with type 2 diabetes and nephropathy, this study was undertaken to investigate the effectiveness and safety of canagliflozin according to the prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation trial. The data indicated that individuals with a previous history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta-blockers, and that, vs placebo, canagliflozin safely decreased renal and cardiovascular events with consistent effects in individuals with and without a prior history of heart failure. These outcomes demonstrate the effectiveness and safety of canagliflozin in patients with type 2 diabetes and nephropathy irrespective of previous history of heart failure.

​

Source